2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Jayesh Mehta, MD, professor of medicine (Hematology and Oncology), Feinberg School of Medicine, Northwestern University, discusses combining agents in multiple myeloma.
Jayesh Mehta, MD, professor of medicine (Hematology and Oncology), Feinberg School of Medicine, Northwestern University, discusses combining agents in multiple myeloma.
In relapsed disease, it has been concluded that 3-drug regimens are better than 2-drug combinations. But, whether they are truly better in patients who may or may not undergo transplant is unclear, says Mehta.
This poses the question of giving more drugs upfront, or introducing drugs later in the disease course. Adding more drugs also brings up the question of cost.
Related Content: